Hydrocortisone Valerate

Summary

Hydrocortisone Valerate (CHEMBL1200562) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 446.6 Da · C26H38O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200562
Name	Hydrocortisone Valerate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5282494
ChEBI	CHEBI:50865
Molecular formula	C26H38O6
Molecular weight	446.6
InChIKey	FZCHYNWYXKICIO-FZNHGJLXSA-N

SMILES: CCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)CO

IUPAC name: [(8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] pentanoate

Also known as: Hydrocortisone valerate, NSC-759133, Westcort, SID855996, HYDROCORTISONE VALERATE, SID56422095, SID144204404, SID170464775

Patent coverage: 2,775 distinct patent families (10,297 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Histone-lysine N-methyltransferase 2A, Cruzipain, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HIF1A	8.3	Potency	5	nM	CHEMBL_ACT_4117796
HIF1A	8.3	Potency	5	nM	CHEMBL_ACT_4519847

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).